You are here: Industry Insights > Ayvakit

News List

CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021 prnasia
July 08, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, presented results from a phase 1/2 clinical study of AYVAKIT® ...
FDA Approves Blueprint Medicines' Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis drugs
June 21, 2021
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (Advanced SM)
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tum prnasia
March 31, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration (NMPA) of China has ...
Blueprint Medicines Receives CRL for Avapritinib americanpharmaceuticalreview
May 20, 2020
Blueprint Medicines announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of avapritinib.
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors worldpharmanews
January 14, 2020
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST
FDA approves Ayvakit, the first targeted gastrointestinal stromal tumour treatment europeanpharmaceuticalreview
January 13, 2020
The US Food and Drug Administration (FDA) has approved the kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring platelet-derived growth factor receptor alpha (PDGFRA) exo
Blueprint Medicines secures FDA approval for Ayvakit pharmaceutical-technology
January 13, 2020
Blueprint Medicines has secured the US Food and Drug Administration (FDA) approval for Ayvakit (avapritinib) for treating unresectable or metastatic gastrointestinal stromal tumour among adults (GIST).